Johnson & Johnson JNJ
NYSE JNJ
$266.34 -0.74 (-0.28%)
As of: Sep 10, 2026 · 3:59 PM EDT

Johnson & Johnson (JNJ) Short term Debt (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Short term Debt came in at $11.7 billion in Q2 2026, up 1.44% year-over-year from $11.5 billion in Q2 2025, and down 33.04% quarter-over-quarter from $17.5 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Short term Debt (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Short term Debt across 18 years of filings, most recently posting $11.7 billion for Q2 2026.

  • In Q2 2026, Short term Debt rose 1.44% year-over-year to $11.7 billion; the TTM figure through Jun 2026 stood at $11.7 billion (up 1.44% YoY), while the FY2025 annual figure was $8.5 billion, up 41.99% from the prior year.
  • Short term Debt came in at $11.7 billion for Q2 2026 at Johnson & Johnson, down from $17.5 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $18.0 billion in Q2 2023 to a low of $3.5 billion in Q4 2023.
  • Average Short term Debt over 5 years is $8.7 billion, with a median of $8.5 billion recorded in 2025.
  • The largest YoY upside for Short term Debt was 318.41% in 2023 against a maximum downside of 72.95% in 2023.
  • Over 5 years, Short term Debt stood at $4.4 billion in 2022, then retreated by 21.99% to $3.5 billion in 2023, then surged by 73.37% to $6.0 billion in 2024, then jumped by 41.99% to $8.5 billion in 2025, then surged by 37.63% to $11.7 billion in 2026.
  • Per Business Quant data, the three most recent Short term Debt figures were $11.7 billion in Q2 2026, $17.5 billion in Q1 2026, and $8.5 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 641.14 Bn 620.38 Bn 17.26 Bn
2 AbbVie 451.04 Bn 444.47 Bn 12.70 Bn
3 Merck 357.43 Bn 350.29 Bn 12.21 Bn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn
5 Pfizer 157.52 Bn 145.82 Bn 10.94 Bn
6 Sanofi 52.14 Bn 44.76 Bn 10.79 Bn
7 Revolution Medicines 42.88 Bn 42.88 Bn -
8 Incyte 24.70 Bn 20.16 Bn 1.57 Bn
9 United Therapeutics 21.47 Bn 18.80 Bn 683.80 Mn
10 Neurocrine Biosciences 15.82 Bn 15.43 Bn 935.80 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 11.69 Bn
Mar 29, 2026 17.46 Bn
Dec 28, 2025 8.50 Bn
Sep 28, 2025 6.39 Bn
Jun 29, 2025 11.53 Bn
Mar 30, 2025 13.90 Bn
Dec 29, 2024 5.98 Bn
Sep 29, 2024 4.46 Bn
Jun 30, 2024 9.86 Bn
Mar 31, 2024 8.55 Bn
Dec 31, 2023 3.45 Bn
Oct 1, 2023 3.87 Bn
Jul 2, 2023 11.70 Bn
Apr 2, 2023 17.98 Bn
Jan 1, 2023 12.76 Bn
Oct 2, 2022 4.42 Bn
Jul 3, 2022 4.31 Bn
Apr 3, 2022 4.30 Bn
Jan 2, 2022 3.77 Bn
Oct 3, 2021 3.80 Bn